Search
for
Sort by
Research 121–150 of 1000+
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
- Therapeutic expansion of JAK inhibitors in Chinese dermatological practice: beyond atopic dermatitis to novel autoimmune frontiers
- Janus kinase (JAK)
- Clinical response to adjunctive platelet-rich plasma injections in a patient with alopecia universalis on oral tofacitinib
- Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
- Upadacitinib for Severe Alopecia Areata in Adults and Adolescents
- Topical Ruxolitinib for the Treatment of Alopecia Universalis
- Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
- An urticarial drug eruption caused by tofacitinib for alopecia universalis
- Baricitinib: A Review in Severe Alopecia Areata
- A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
- British Association of Dermatologists living guideline for managing people with alopecia areata 2025
- Successful treatment of resistant alopecia totalis with tofacitinib
- EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata
- Novel investigational drugs for alopecia areata and future perspectives
- P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
- A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
- 93 Approach to Managing Recalcitrant Alopecia Areata With Combination Therapy: A Series of Five Cases in Black Pediatric Patients
- Alopecia Areata Barbae in a Nutshell
- Survey of pediatric dermatologist views on treatment for alopecia areata
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- Alopecia areata
- Current Treatments for Alopecia Areata